Melanocytic Lesions: Difference between revisions

He.Fang (talk | contribs)
change fond for the tables
He.Fang (talk | contribs)
No edit summary
Line 839: Line 839:
{| class="wikitable"
{| class="wikitable"
|'''Gene'''
|'''Gene'''
|'''Function/Potential Role (S11)'''
|'''Function / Potential Role'''
|'''Gene'''
|'''Function/Potential Role (S12)'''
|-
|-
|''ADAM30''
|''ADAM30''
|Limited functional evidence
|Limited functional evidence supporting a driver role in melanoma
|''CALML5''
|Calcium-binding protein
|-
|-
|''BPTF''
|''BPTF''
|Chromatin remodeler
|Chromatin remodeler with context-dependent oncogenic properties
|''CD274''
|Immune checkpoint regulator
|-
|-
|''CYP24''
|''CYP24''
|Vitamin D metabolism
|Vitamin D metabolism gene; indirect relevance to tumor biology
|-
|''EP300''
|Histone acetyltransferase; may function as coactivator or tumor suppressor depending on context
|-
|''KIRREL''
|Limited mechanistic validation as melanoma driver
|-
|''MKL1''
|Transcriptional coactivator; context-dependent oncogenic activity
|-
|''NOTCH2''
|Context-dependent signaling with oncogenic and tumor-suppressive roles depending on cellular context
|-
|''PDE11A''
|Phosphodiesterase with unclear contribution to melanoma progression
|-
|''PDE4DIP''
|Scaffold protein; no consistent evidence of recurrent oncogenic activation in melanoma
|-
|''PHIP''
|Implicated in melanoma progression but mechanistically complex and not a canonical oncogene
|-
|''PIK3C2G''
|PIK3 family member; limited evidence of recurrent activating alterations in melanoma
|-
|''S100A9, S100A10, S100A11, S100A12''
|Inflammatory mediators more commonly implicated in tumor microenvironment modulation than as primary genomic drivers
|-
|''SS18L1''
|Transcriptional regulator without clear melanoma driver validation
|-
|''CALML5''
|Calcium-binding protein; limited oncogenic validation
|-
|''CD274 (PD-L1)''
|Immune checkpoint regulator; deletion effects are context-dependent
|-
|''CDK10''
|''CDK10''
|Cell-cycle regulator
|Cell-cycle regulator; limited melanoma-specific driver evidence
|-
|-
|''EP300''
|Histone acetyltransferase
|''CHEK1''
|''CHEK1''
|DNA damage kinase
|DNA damage response kinase; dual context-dependent role
|-
|-
|''KIRREL''
|Limited driver validation
|''ETS1''
|''ETS1''
|Transcription factor
|Transcription factor with context-dependent oncogenic properties
|-
|-
|''MKL1''
|Transcriptional coactivator
|''IL15RA''
|''IL15RA''
|Immune regulatory receptor
|Immune regulatory receptor; indirect tumor role
|-
|-
|''NOTCH2''
|Signaling (context-dependent)
|''JAK2''
|''JAK2''
|Oncogenic kinase
|Oncogenic kinase; loss not typical driver event in melanoma
|-
|-
|''PDE11A''
|Phosphodiesterase
|''LARP4B''
|''LARP4B''
|RNA-binding protein
|RNA-binding protein; insufficient evidence as melanoma driver
|-
|-
|''PDE4DIP''
|Scaffold protein
|''MYB''
|''MYB''
|Canonical oncogene
|Canonical oncogene; loss does not represent typical driver mechanism in melanoma
|-
|-
|''PHIP''
|Implicated in progression
|''NET1''
|''NET1''
|RhoA GEF
|RhoA GEF; limited melanoma-specific evidence
|-
|-
|''PIK3C2G''
|PIK3 family member
|''PRDM16''
|''PRDM16''
|Transcriptional regulator
|Context-dependent transcriptional regulator; not established as recurrent melanoma tumor suppressor
|-
|-
|''S100A9-12''
|Inflammatory mediators
|''PRKCQ''
|''PRKCQ''
|Signaling kinase
|Kinase with signaling roles; melanoma-specific driver role unclear
|-
|-
|''SS18L1''
|Transcriptional regulator
|''YAP1''
|''YAP1''
|Hippo pathway oncogene
|Hippo pathway oncogene; deletion suggests complex regional effects
|}
|}


==Reference==
==Reference==